Rhenium Re 188 etidronateAlternative Names: 188Re -HEDP
Latest Information Update: 07 Jan 2016
At a glance
- Originator Jiangsu Lai Tai Medical Biotechnology
- Developer Jiangsu Lai Tai Medical Biotechnology; Shanghai Institute of Applied Physics Chinese Academy of Sciences
- Class Antineoplastics; Bisphosphonates; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cancer pain
Most Recent Events
- 07 Jan 2016 Phase-II clinical trials in Cancer pain in China (IV)